Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsTirzepatide is proving its worth early in type 2 diabetes. A new analysis of the SURPASS-EARLY trial found that tirzepatide significantly improved beta-cell function and insulin sensitivity compared to intensified conventional care. The results suggest starting tirzepatide early in the disease course could help more patients achieve — and sustain — normal blood sugar levels.
A new prespecified analysis of the SURPASS-EARLY trial reveals that tirzepatide (Mounjaro, Eli Lilly) doesn't just lower blood sugar — it improves the underlying biology behind it. In people with recent-onset type 2 diabetes (T2D), tirzepatide significantly outperformed intensified conventional care (ICC) on key markers of beta-cell function and insulin sensitivity, helping explain why it delivers such superior glycemic control.
The trial enrolled 794 people with T2D of four years or fewer who were inadequately managed on metformin. At 104 weeks, tirzepatide drove A1c down to a mean of 5.56% vs. 6.3% with ICC, and nearly 70% of tirzepatide patients achieved normoglycemia — more than double the ICC rate of 28.1%. Weight loss was also dramatically greater: 15.8 kg vs. 6.5 kg.
Why it matters: These findings suggest tirzepatide may do more than manage symptoms — it could help preserve and restore beta-cell function when started early. Researchers are still untangling how much of the benefit comes from weight loss vs. direct metabolic effects, but clinicians are being encouraged to consider earlier initiation of tirzepatide in T2D management guidelines.